FTC

January 26, 2024

KJ Boyle

Blog Post Anti-MonopolyFTCPharma

The FTC Ain’t Nothin to Mess With

The FTC has won its lawsuit against Martin Shkreli, the pharmaceutical executive infamous for jacking up the price of the antiparasitic drug Daraprim from $13.50 to $750 overnight in 2015 and later using his ill-gotten fortune to buy an exclusive Wu-Tang Clan album for $2 million. Shkreli is the quintessential corporate ghoul, having already racked up convictions for securities fraud—which resulted in an indefinite ban from the securities industries—and failure to pay $1.26 million in New York state taxes. Now, his price gouging has finally caught up with him, as the FTC successfully argued that he spearheaded an anti-competitive scheme to monopolize the drug. The presiding judge found Shkreli’s conduct to be “egregious, deliberate, repetitive, long-running, and ultimately dangerous,” issuing a $64.6 million fine and imposing a lifetime ban from the pharmaceutical industry. 

August 02, 2023 | Revolving Door Project Newsletter

Andrea Beaty

Newsletter Anti-MonopolyCongressional OversightDepartment of JusticeFTCGovernment Capacity

Following Failed Hearing, Jim Jordan And Republicans Try New Tacks To Take Down Khan and Kanter

Two weeks ago, Federal Trade Commission (FTC) Chair Lina Khan entered a House Judiciary  Committee hearing with a target on her back. In the leadup to the hearing, Republicans readied their trumped-up attacks against Khan and the agency she leads: a barely relevant memo from a conflicted ethics officer, a list of unfounded grievances from bitter former Commissioner Christine Wilson, and absurd defenses of Elon Musk’s lazy privacy practices at Twitter. But Khan emerged unscathed, and by the end, the Republicans had lost all their fire.

July 17, 2023

KJ Boyle

Blog Post Anti-MonopolyCongressional OversightEthics in GovernmentFTCTech

Lina Khan Unscathed By Conflicted Ethics Officer and Pro-Monopoly Republicans

Rep Jim Jordan and company had already been eyeing Khan for an investigation because she had the audacity to enforce a consent decree that Twitter violated under Elon Musk’s leadership. Then, they eagerly seized on last month’s (conveniently timed) reporting from Bloomberg which published a previously unseen memo from an FTC ethics official and accused Chair Khan of ignoring the official’s recommendation. With that backdrop, the Republicans seemed poised to strike while the iron was hot, a culmination of their years-long project to undermine Khan’s leadership and reputation. The result was … much different. Thanks to some sleuthing on our part and the bipartisan support for taking on tech monopolies, yesterday’s hearing was less a damning inquisition and more a victory lap for Khan’s rejuvenation of the FTC.

July 13, 2023

Andrea Beaty

Press Release

Anti-MonopolyCongressional OversightFTC

RELEASE: Via Baseless Attacks On Khan, House Republicans Continue to Serve their Monopolist Funders

“Today’s hearing further proved that Republican’s attacks on Lina Khan and her leadership are blatant attempts to weaken antitrust enforcement to the benefit of the corporations that fund the Republican Party. Members, including Jim Jordan, focused on baseless allegations in an attempt to delegitimize the work the FTC is doing to crack down on anti-competitive and harmful practices that monopolistic companies use to amass economic power and squeeze profits out of consumers and workers.” 

July 05, 2023 | The American Prospect

KJ Boyle

Op-Ed Anti-MonopolyEthics in GovernmentFTCIndependent Agencies

Lina Khan Haters Took A Premature Victory Lap

It turns out that the ethics official who recommended that Khan recuse herself from a case involving Meta is an owner of Meta stock. This ethics judgment was music to the ears of the media organizations, Republicans, and antitrust hacks who have been attacking Lina Khan throughout her leadership. Beyond being wrong and selective in singling out FTC officials for ethics concerns, the problem with Pankey’s opinion is deeply ironic. Pankey herself has a legitimate conflict of interest in relation to Meta.